Nebracetam

From Wikipedia, the free encyclopedia

Template:Short description Template:Cs1 config Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Nebracetam
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
ATC codePage Template:Plainlist/styles.css has no content.
  • none
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Identifiers
  • (RS)-4-(Aminomethyl)-1-benzylpyrrolidin-2-one
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC12H16N2O
Molar mass204.273 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
ChiralityRacemic mixture
  • O=C2N(Cc1ccccc1)CC(C2)CN
  • InChI=1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2 checkY
  • Key:LCAFGJGYCUMTGS-UHFFFAOYSA-N checkY
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content. ☒NcheckY (what is this?)Page Template:Nobold/styles.css has no content.  (verify)

Nebracetam is an investigational drug of the racetam family that is a M1 acetylcholine receptor agonist in rats.[1] Based on a human leukemic T cell experiment in 1991, it is believed to act as an agonist for human M1-muscarinic receptors.[2] It is also believed to act as a nootropic, like many other racetam drugs.[3] A chemoenzymatic method of synthesis was reported in 2008.[4] As of 2023, human trials have not yet been conducted.

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content.Takeo S, Hayashi H, Miyake K, Takagi K, Tadokoro M, Takagi N, et al. (June 1997). "Effects of delayed treatment with nebracetam on neurotransmitters in brain regions after microsphere embolism in rats". British Journal of Pharmacology. 121 (3): 477–484. doi:10.1038/sj.bjp.0701161. PMC 1564714. PMID 9179389.
  2. ^ Page Module:Citation/CS1/styles.css has no content.Kitamura Y, Kaneda T, Nomura Y (January 1991). "Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist". Japanese Journal of Pharmacology. 55 (1): 177–180. doi:10.1254/jjp.55.177. PMID 2041225.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Gabryel B, Pudełko A, Trzeciak HI, Cieślik P (2000). "Effect of nebracetam on content of high-energy phosphates and morphometry of rat astrocytes in vitro. Comparison with piracetam". Acta Poloniae Pharmaceutica. 57 (4): 289–298. PMID 11126618.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Yamashita S, Mase N, Takabe K (2008-09-22). "Chemoenzymatic total synthesis and determination of the absolute configuration of (S)-nebracetam". Tetrahedron: Asymmetry. 19 (18): 2115–2118. doi:10.1016/j.tetasy.2008.09.004. ISSN 0957-4166.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Template:Muscarinic acetylcholine receptor modulators

Template:Asbox